Home › Funds › RA CAPITAL MANAGEMENT, L.P. › EWTX
RA CAPITAL MANAGEMENT, L.P. position in EWTX
EDGEWISE THERAPEUTICS INC · Health Care
RA CAPITAL MANAGEMENT, L.P. reported holding 8,392,730 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$340.7M, representing 3.51% of its reported portfolio and ranking #5 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed EWTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How RA CAPITAL MANAGEMENT, L.P.'s EWTX position evolved
RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in EWTX in Q1 2024 at 8,909,091 shares (US$162.5M). The position peaked in Q2 2026 at 8,392,730 shares, worth US$341.0M. Across 11 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 8,392,730 shares valued at US$340.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 8.91M | $162.50M | New |
| Q2 2024 | 8.91M | $160.45M | Hold |
| Q3 2024 | 8.91M | $237.78M | Hold |
| Q4 2024 | 8.91M | $237.87M | Hold |
| Q1 2025 | 8.91M | $196.00M | Hold |
| Q2 2025 | 9.90M | $129.82M | Add |
| Q3 2025 | 10.43M | $169.15M | Add |
| Q4 2025 | 10.43M | $258.78M | Hold |
| Q1 2026 | 10.43M | $328.50M | Hold |
| Q2 2026 | 8.39M | $341.00M | Reduce |
| Q3 2026 | 8.39M | $340.74M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EWTX and 13F data
EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.1M), Paradigm Biocapital Advisors LP (US$437.6M), Novo Holdings A/S (US$217.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EWTX
- ORBIMED ADVISORS LLC 15.52M sh · $630.05M · Q3 2026
- Paradigm Biocapital Advisors LP 10.78M sh · $437.61M · Q3 2026
- Novo Holdings A/S 5.35M sh · $217.21M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.40M sh · $178.72M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.14M sh · $168.01M · Q3 2026
- BAKER BROS. ADVISORS LP 3.70M sh · $150.29M · Q3 2026
- Siren, L.L.C. 2.80M sh · $113.85M · Q3 2026
- First Light Asset Management, LLC 2.48M sh · $100.81M · Q3 2026
- BRAIDWELL LP 2.07M sh · $84.01M · Q3 2026
- Cormorant Asset Management, LP 1.86M sh · $75.52M · Q3 2026
- MPM BioImpact LLC 1.58M sh · $63.99M · Q3 2026
- Deep Track Capital, LP 1.15M sh · $46.64M · Q3 2026
More on RA CAPITAL MANAGEMENT, L.P.
FAQ
How long has RA CAPITAL MANAGEMENT, L.P. held EWTX?
RA CAPITAL MANAGEMENT, L.P. has disclosed EWTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in EWTX?
As of Q3 2026, RA CAPITAL MANAGEMENT, L.P. holds 8.39M shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $340.74M, representing 3.51% of its reported portfolio and ranking #5.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling EWTX?
In the latest 13F filing (Q3 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in EWTX. The position peaked in Q2 2026 at 8.39M shares.
Which other funds hold EWTX?
Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, Paradigm Biocapital Advisors LP, Novo Holdings A/S, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.